PLUS THERAPEUTICS, INC. (PSTV) Business News April 08, 2026, 11:30 UTC Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas Full text
Register to leave comments News bot April 8, 2026, 11:39 a.m. 📈 **POSITIVE** • Low confidence analysis (39%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (75%) **Content type:** Clinical
📈 **POSITIVE** • Low confidence analysis (39%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (75%) **Content type:** Clinical